bioRxiv Science⌕ Search

Biology subjects

Desai, K. V.

Publications and source records attributed to Desai, K. V..

3 recordsLinked to original sources

JMJD6 and YBX1 physically interact and regulate HOTAIR proximal promoter

In a previous study, we showed JMJD6 interacted with HOTAIR promoter (-123 to -103 bp upstream of TSS, JIR) and augmented its transcription. Maximal JMJD6 mediated induction required (-216 to -123 bp) region. In silico prediction and ENCODE data suggested that YBX1 could be that potential candidate and in this study the region is designated as YBX1 interacting region (YIR). In breast cancer cell lines, we show that JMJD6 and YBX1 regulate each others expression and physically interact with each other when recombinantly expressed, as endogenous proteins and when synthesized in vitro. Domain mapping indicated that A/P domain of YBX1 interacted with JMJC domain of JMJD6. Luciferase activity of HOTAIR promoter constructs, pHP216 and pHP123, increased in presence of YBX1 in MCF7, Vec and JMJD6 overexpressing JOE cells but was lost in the presence of JMJD6 and YBX1 siRNAs. Interestingly, activity of pHP123 that lacks YIR also decreased upon YBX1 knock out (YKO). Next, by individual JMJD6, YBX1 and ChIP-re-ChIP assays we demonstrate that both proteins co-occupy this promoter region. Further, electrophoretic mobility shift assays showed that YIR probes retarded two complexes, which lost intensity in YKO cells. Interestingly, JIR-protein complex disappeared in YKO cells. Together these data imply that YBX1 not only enhanced promoter activity but may also be involved in JMJD6 recruitment. Taken together, our data proposes that the interaction and positive feed forward loop perpetuated by JMJD6 and YBX1 may culminate in HOTAIR induction, which in turn is known to drive tumor progression.

cancer biology↗

Construction of ceRNA networks in endocrine therapy resistance model systems

BackgroundEndocrine therapy resistance (ETR) in breast cancer is achieved via multiple pathways including a decrease in ER, dysregulation of cell cycle genes, and/or mutations in ER/co-activators/co-repressors. We have reported earlier that high expression of Jumonji domaining containing protein 6 (JMJD6) induced ETR by depleting ER expression. In this study, 3 cellular models representing distinct ETR pathways; Tamoxifen resistant (TAMR), Long-term Estrogen deprived (LTEDI), JMJD6 overexpressing (JOE) cells, and parental MCF7 were subjected to RNA-sequencing, CNC, and ceRNA network analysis. We hypothesised that post-comparison RNA regulations that are common to all cell lines, will reveal actionable markers and targets. These will be shared by all patients with ET-resistant disease, independent of the initiating event. Results170 differentially expressed genes were found, of these, 73 maintained the same directionality in expression (ETR cassette genes). These genes segregated TCGA ER+ tumors into two groups, one intermixing with ER-tumors. Pathway-based curation of ETR genes identified 21 genes (7 up- and 14 down-regulated) that participated in multiple cancer hallmark pathways. Genes upregulated in ETR cells were less expressed in ER+ tumors at diagnosis when compared to normal breast samples but their higher expression indicated adverse survival outcomes. Next, these genes were used for CNC and ceRNA network construction and a triad FLT4:MIR503HG:miR-497/195/424 was discovered. The expression levels of miRNAs were predicted via network analysis and quantitative RT-PCR was used to validate the down regulation of miR-497/195/424 and upregulation of their targets, FLT4 and MIR503HG in ETR cells. ConclusionsWe show that total RNA-seq data can be successfully used to predict actionable miRNAs that achieve drug resistance. Re-expression of ETR genes such as FLT4 in tumor cells, that are less expressed at diagnosis, may be indicative of ETR onset. Finally, ETR may arise due to suppression of miR-424/497/195 leading to higher expression of FLT4 and MIR503HG. We posit that FLT4 may be a suitable target and RT-PCR analysis of this RNA triad could be developed as a detection strategy for ETR in ER+ breast cancer.

cancer biology↗

Exploiting gene expression profiles of circulating extracellular vesicles for breast cancer detection

BackgroundLiquid biopsy-based biomarkers offer several advantages since they are minimally invasive, can be useful in longitudinal monitoring of the disease and have higher patient compliance. We hypothesize that RNA content of circulating EVs differs in breast cancer patients and healthy women. EV RNAs may provide an opportunity to diagnose, detect subtypes and metastatic states. Experimental DesignRNA-seq analysis and qRT-PCR from matched tumor biopsy, circulating EVs from breast cancer patients (EV-C) and healthy donors (EV-H) was performed to find genes that discriminate between these groups. ResultsEV-C to EV-H comparison yielded 320 DEGs (adjusted p value [≤]0.05) enriched for cancer related pathways like Myc, Reactive oxygen species, and Angiogenesis. Allograft rejection and Interferon pathway genes were over-represented in the cancer group. Top 6 genes were validated by qRT-PCR in a validation cohort. 5 genes consistently and correctly classified cancer and healthy groups. An independent set of 374 and 640 DEGs could segregate ER positive/ER negative and non-metastatic versus metastatic samples, respectively. EVs from metastatic samples had higher variability in gene expression patterns whereas those from non-metastatic samples showed better correlation. Ability of 4 genes to classify metastases state was explored. ConclusionWe report five EV RNAs that can be used to diagnose breast cancer in a subtype independent manner. Initial analysis indicates that EV RNA content differs based on subtype specificity and metastasis status.

cancer biology↗